# Atherosclerosis

Manage atherosclerosis as established or high-risk subclinical ASCVD: identify the affected vascular bed, intensify LDL-C reduction, use coronary calcium selectively when treatment is uncertain, and escalate beyond statins when residual LDL-C remains at least 70 mg/dL.

**Clinical question:** How should physicians stratify atherosclerosis and select lipid-lowering intensity for clinical or subclinical ASCVD?

Updated: 2026-09-15T22:35:17.860248+00:00

## What matters in practice
- Clinical PAD is ASCVD: prescribe high-intensity statin therapy targeting at least a 50% LDL-C reduction. [4]
- For PAD with LDL-C at least 70 mg/dL despite maximally tolerated statin therapy, add ezetimibe or a PCSK9 inhibitor. [4]
- Use coronary artery calcium selectively when the primary-prevention treatment decision remains uncertain after 10-year risk assessment; CAC 0 can support deferring a statin only when key exceptions are absent. [3][7]
- In established ASCVD, evolocumab reduced the FOURIER primary composite endpoint by 15% and cardiovascular death, myocardial infarction, or stroke by 20% among patients with LDL-C at least 70 mg/dL. [12]

## Separate clinical ASCVD from uncertain primary prevention

The treatment intensity decision follows whether atherosclerosis is already clinically manifest.

Treat coronary artery disease, atherothrombotic brain infarction, and peripheral artery disease as clinical ASCVD rather than as risk-factor-only disease. These phenotypes carry secondary-event risk and support intensive LDL-C lowering with a statin, with ezetimibe or PCSK9 inhibition when further reduction is required. [14]

For patients without clinical ASCVD, begin with formal cardiovascular risk assessment and a clinician-patient treatment discussion. When risk remains uncertain after 10-year risk assessment, coronary artery calcium (CAC) can reclassify risk and determine whether lipid-lowering therapy should be initiated or deferred. [3][7]

Document the vascular distribution of disease because atherosclerosis is systemic and may involve coronary, cerebrovascular, and peripheral arterial beds. PAD in particular should trigger secondary-prevention lipid management rather than management based only on calculated primary-prevention risk. [1][4][16]
- Clinical ASCVD: proceed directly to maximally tolerated high-intensity statin therapy; do not use CAC to decide whether secondary prevention is needed. [4][14]
- No clinical ASCVD but treatment uncertainty: use CAC as a risk modifier after, rather than instead of, 10-year risk assessment. [3][7]
- Known disease in more than one arterial bed: recognize polyvascular atherosclerosis as a high-risk phenotype requiring aggressive secondary prevention. [10]

*Risk category determines whether imaging refines a decision or lipid lowering should be intensified immediately. [3][4][7][14]*

| Clinical setting | Immediate decision | Role of further atherosclerosis imaging |
| --- | --- | --- |
| Established CAD, atherothrombotic brain infarction, or PAD | Initiate or maintain high-intensity statin therapy; pursue at least 50% LDL-C reduction in PAD. [4][14] | Do not delay secondary prevention for CAC-based risk reclassification. [4][14] |
| No clinical ASCVD; primary-prevention risk uncertain after 10-year assessment | Obtain CAC if the result will alter the statin decision. [3][7] | CAC strata guide statin initiation, intensification, or deferral. [3] |
| Subclinical plaque already documented | Consider high-intensity statin therapy and an LDL-C goal below 70 mg/dL. [3] | Additional imaging is not needed solely to establish that plaque is present. [3] |

## Use coronary calcium only when its result changes statin management

CAC is most useful for borderline or intermediate-risk patients with an unresolved treatment decision.

A CAC score of 0 supports deferring statin therapy in selected patients, but not in those with diabetes, LDL-C at least 190 mg/dL, current smoking, or a family history of premature cardiovascular disease. If statin therapy is deferred after CAC 0, repeat CAC in 3 to 5 years. [3]

For CAC 1 to 99 Agatston units and below the 75th percentile, consider a moderate-intensity statin and an LDL-C target below 100 mg/dL; escalation to high-intensity therapy may be appropriate. [3]

For CAC at least 100 Agatston units or at least the 75th percentile, consider moderate- or high-intensity statin therapy with LDL-C below 70 mg/dL; ezetimibe can be considered. CAC at least 1,000 identifies a particularly high plaque burden for which at least 50% LDL-C reduction and LDL-C below 70 mg/dL are proposed, with consideration of high-intensity statin, ezetimibe, and PCSK9 inhibition. [3]
- Order CAC to resolve a treatment decision, not as universal screening. [3][7]
- Do not interpret CAC 0 as low risk when diabetes, severe hypercholesterolemia, smoking, or premature family history is present. [3]
- Treat incidental or previously documented substantial subclinical atherosclerosis as a reason to consider high-intensity statin therapy rather than repeatedly reassessing baseline risk. [3]

*CAC strata and corresponding lipid-management implications. [3]*

| CAC result | Management implication | Exception or follow-up |
| --- | --- | --- |
| 0 Agatston units | Statin may be deferred. [3] | Do not defer for diabetes, LDL-C at least 190 mg/dL, smoking, or premature family history; repeat CAC in 3-5 years if deferring therapy. [3] |
| 1-99 Agatston units and below 75th percentile | Consider moderate-intensity statin and LDL-C below 100 mg/dL; high-intensity therapy may be considered. [3] | Interpret in the context of overall risk and treatment preference. [3][7] |
| At least 100 Agatston units or at least 75th percentile | Consider moderate- or high-intensity statin with LDL-C below 70 mg/dL; consider ezetimibe. [3] | Represents a treatment-intensifying result. [3] |
| At least 1,000 Agatston units | Consider high-intensity statin, ezetimibe, and PCSK9 inhibitor; target at least 50% LDL-C reduction and LDL-C below 70 mg/dL. [3] | Manage as extensive subclinical atherosclerotic burden. [3] |

## Escalate LDL-C lowering in established atherosclerotic disease

LDL-C lowering reduces atherosclerotic cardiovascular events; use a stepwise regimen anchored by maximally tolerated statin therapy.

LDL-C is a causal factor in atherosclerotic cardiovascular disease, and randomized-trial evidence links LDL-C reduction to proportional reductions in cardiovascular events. In PAD, high-intensity statin therapy is indicated with an intended LDL-C reduction of at least 50%. [4][12]

Recheck LDL-C after establishing maximally tolerated statin therapy. In PAD, LDL-C at least 70 mg/dL despite maximally tolerated statin is the threshold at which adding ezetimibe is reasonable; adding a PCSK9 inhibitor is also reasonable. [4]

Ezetimibe is the preferred first add-on in older ACC nonstatin guidance because of safety and tolerability. If LDL-C goals remain unmet on maximally tolerated statin plus ezetimibe, a PCSK9 inhibitor can be added; bile acid sequestrants are a second-line option when ezetimibe is not tolerated and triglycerides are not elevated. [11]

For patients qualifying for PCSK9 monoclonal antibody therapy, FDA-labeled regimens cited for alirocumab are 75 mg subcutaneously every 2 weeks, with uptitration to 150 mg every 2 weeks; evolocumab is 140 mg subcutaneously every 2 weeks or 420 mg every 4 weeks. Both are indicated with statins for heterozygous familial hypercholesterolemia or known ASCVD requiring further LDL-C reduction despite lifestyle intervention and maximally tolerated statin therapy. [11]
- PAD plus LDL-C at least 70 mg/dL on maximally tolerated statin: add ezetimibe or a PCSK9 inhibitor. [4]
- Heterozygous familial hypercholesterolemia or known ASCVD requiring additional LDL-C lowering: alirocumab or evolocumab may be used with statin therapy. [11]
- Homozygous familial hypercholesterolemia: evolocumab also has an FDA approval cited for this population. [11]

### Selecting an add-on agent

Select ezetimibe when a well-tolerated oral first add-on is appropriate. Select a PCSK9 inhibitor when substantial additional LDL-C lowering is required after maximally tolerated statin therapy, particularly in known ASCVD or familial hypercholesterolemia meeting labeled use. [11]
- Avoid positioning bile acid sequestrants as the default add-on: use them only when ezetimibe is not tolerated and triglycerides are not elevated. [11]
- For breastfeeding patients, avoid statins, ezetimibe, and PCSK9 inhibitors; a bile acid sequestrant can be continued when necessary. [3]

*Stepwise LDL-C treatment escalation for atherosclerotic disease. [4][11][12]*

| Step | When to use | Agent or action |
| --- | --- | --- |
| 1 | Clinical PAD or other established ASCVD | Use maximally tolerated high-intensity statin; in PAD target at least 50% LDL-C reduction. [4][14] |
| 2 | PAD with LDL-C at least 70 mg/dL on maximally tolerated statin | Add ezetimibe; PCSK9 inhibitor is also reasonable. [4] |
| 3 | Further LDL-C lowering required in known ASCVD or heterozygous familial hypercholesterolemia despite statin therapy | Alirocumab 75 mg SC every 2 weeks, with uptitration to 150 mg every 2 weeks, or evolocumab 140 mg SC every 2 weeks or 420 mg every 4 weeks. [11] |
| Alternative | Ezetimibe not tolerated and triglycerides not elevated | Consider a bile acid sequestrant. [11] |

## Recognize phenotypes that justify earlier or more intensive prevention

Calculated short-term risk can understate risk in extensive subclinical disease and younger adults.

Document diabetes, elevated blood pressure, smoking, overweight status, dietary factors, physical inactivity, and inadequate sleep because each is associated with ASCVD risk and can identify a high-risk primary-prevention phenotype when combined with subclinical plaque. [17]

Measure and act on the full atherogenic-risk context in younger adults rather than relying exclusively on short-term event prediction. Apolipoprotein B and lipoprotein(a) can inform long-term ASCVD risk, while CAC and polygenic risk scores have potential utility but uncertain optimal use in this population. [23]

An elevated lipoprotein(a) concentration can substantially increase estimated lifetime ASCVD risk; specific highly effective messenger RNA-targeted Lp(a)-lowering therapies remain in clinical development. Use the result to intensify management of modifiable risk factors and LDL-C rather than waiting for an Lp(a)-specific drug. [23]
- Diabetes accelerates ASCVD and supports active lipid management; supplemental LDL-C lowering with ezetimibe or PCSK9 inhibition is relevant when guideline LDL-C levels are not achieved. [21]
- Use subclinical atherosclerosis to identify high-risk primary-prevention patients whose lifetime risk may not be captured by a primary-versus-secondary prevention dichotomy. [17]
- Do not substitute emerging inflammatory or genetic strategies for established LDL-C lowering; their best clinical role remains unsettled. [22][23]

*Risk modifiers that alter interpretation of apparently low short-term risk. [3][17][21][23]*

| Finding | Clinical implication | Actionable next step |
| --- | --- | --- |
| Diabetes | Accelerated ASCVD risk. [21] | Do not use CAC 0 alone to defer statin therapy. [3] |
| LDL-C at least 190 mg/dL | CAC 0 does not support statin deferral. [3] | Treat as a statin-indicated exception to CAC-guided deferral. [3] |
| Elevated Lp(a) | May substantially increase lifetime ASCVD risk. [23] | Intensify management of modifiable risk factors and LDL-C. [23] |
| Documented subclinical plaque | Identifies high-risk primary prevention. [17] | Consider high-intensity statin therapy and LDL-C below 70 mg/dL. [3] |

## Monitor LDL-C response and use imaging selectively

The follow-up target is treatment response and event prevention, not serial plaque imaging.

Monitor LDL-C to establish whether statin therapy produces the intended response and whether the LDL-C threshold for add-on therapy has been reached. In PAD, an LDL-C value at least 70 mg/dL on maximally tolerated statin should prompt a documented choice between adding ezetimibe and adding a PCSK9 inhibitor. [4]

Do not use serial coronary CT angiography as a routine surrogate for treatment success. In PARADIGM, statin use was associated with lower risk of annualized total plaque-volume increase above the cohort median, but was not associated with progression to at least 50% diameter stenosis on follow-up coronary CT angiography. [5]

For a patient in whom CAC 0 led to statin deferral, repeat CAC after 3 to 5 years. Otherwise, repeat imaging should be driven by a new clinical question rather than by a desire to document plaque regression. [3][5]
- Track LDL-C response against the PAD goal of at least 50% reduction and the escalation threshold of at least 70 mg/dL. [4]
- Use repeat CAC only in the specific CAC 0 deferral pathway, at 3-5 years. [3]
- Do not equate a change in CT plaque phenotype or volume with a stand-alone indication to alter treatment without considering LDL-C and clinical risk. [5]

*Follow-up actions tied to measurable treatment decisions. [3][4][5]*

| Follow-up finding | Interpretation | Next action |
| --- | --- | --- |
| PAD on maximally tolerated statin with LDL-C below 70 mg/dL | Below the guideline threshold cited for adjunctive therapy. [4] | Continue lipid-lowering regimen and longitudinal ASCVD prevention. [4] |
| PAD on maximally tolerated statin with LDL-C at least 70 mg/dL | Residual LDL-C elevation despite statin. [4] | Add ezetimibe or a PCSK9 inhibitor. [4] |
| CAC 0 with statin deferred | Risk reassessment interval is due after 3-5 years. [3] | Repeat CAC and reconsider therapy based on current risk profile. [3] |
| Serial CCTA shows plaque progression | Plaque-volume progression is not interchangeable with progression to at least 50% stenosis. [5] | Reassess LDL-C lowering and clinical risk rather than treating imaging alone. [5] |

## References
1. Parsing Atherosclerosis | Circulation — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.116.022971
2. 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIR.0b013e3182051b4c
3. A Critical Appraisal of Lipid Management in the Post-Statin Era - JACC — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacadv.2025.101823
4. 2026 ACC/AHA Clinical Performance and Quality Measures for Patients With Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2025.09.003
5. Effects of Statins on Coronary Atherosclerotic Plaques: The PARADIGM Study — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jcmg.2018.04.015
6. Anti-atherosclerotic therapies: Milestones, challenges, and ... — www.cell.com — https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(22)00553-6
7. Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2666667722000228
8. Review of Clinical Practice Guidelines for the Management of LDL ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0735109714025911
9. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0890509620305045
10. Polyvascular disease: A narrative review of current evidence and a consideration of the role of antithrombotic therapy - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0021915020314957
11. PCSK9 inhibition: A promise fulfilled? | Cleveland Clinic Journal of medicine — www.ccjm.org — https://www.ccjm.org/content/83/11_suppl_2/S36
12. LDL-Cholesterol-Lowering Therapy - Prevention and Treatment of Atherosclerosis - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK584301
13. Landmark Lipid‐Lowering Trials in the Primary Prevention of Cardiovascular Disease - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC6649586
14. Lipid Management for Secondary Prevention in Atherosclerotic ... — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12979944
15. Current and Emerging Therapies in Atheroprotection - NCBI - NIH — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK534263
16. Carotid Atherosclerosis - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/carotid-atherosclerosis
17. Identification and management of patients at high-risk for ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S266666772500340X
18. Lipoprotein(a) in Japanese Patients With Cardiovascular Disease — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2772374725004624
19. The Effect of Lipid-Lowering Therapy on Coronary Artery Plaque in ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2772374725003138
20. Concomitant Carotid and Coronary Artery Disease Management — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0890509624005922
21. Lipid-lowering in diabetes: An update - ScienceDirect.com — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0021915023052346
22. An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S014929182300320X
23. Managing Atherosclerotic Cardiovascular Risk in Young Adults — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0735109721084448
24. American Journal of Preventive Cardiology - ScienceDirect.com — www.sciencedirect.com — https://www.sciencedirect.com/journal/american-journal-of-preventive-cardiology/articles-in-press

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.